» Articles » PMID: 16893894

Structural and Functional Evidence for the Role of the TLR2 DD Loop in TLR1/TLR2 Heterodimerization and Signaling

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2006 Aug 9
PMID 16893894
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The Toll/Interleukin-1 receptor (TIR) domain of the Toll-like receptors (TLRs) plays an important role in innate host defense signaling. The TIR-TIR platform formed by the dimerization of two TLRs promotes homotypic protein-protein interactions with additional cytoplasmic adapter molecules to form an active signaling complex resulting in the expression of pro- and anti-inflammatory cytokine genes. To generate a better understanding of the functional domains of TLR2 we performed a random mutagenesis analysis of the human TLR2 TIR domain and screened for TLR2/1 signaling-deficient mutants. Based upon the random mutagenesis results, we performed an alanine scanning mutagenesis of the TLR2 DD loop and part of the alphaD region. This resulted in the identification of four residues crucial for TLR2/1 signaling: Arg-748, Phe-749, Leu-752, and Arg-753. Computer-assisted energy minimization and docking studies indicated three regions of interaction in the TLR2/1 TIR-docked heterodimer. In Region I, residues Arg-748 and Phe-749 in TLR2 DD loop were involved in close contacts with Gly-676 in the TLR1 BB loop. Because this model suggested that steric hindrance would significantly alter the binding interactions between DD loop of TLR2 and BB loop of TLR1, Gly-676 in TLR1 was rationally mutated to Ala and Leu. As expected, in vitro functional studies involving TLR1 G676A and TLR1 G676L resulted in reduced PAM(3)CSK(4) mediated NF-kappaB activation lending support to the computerized predictions. Additionally, mutation of an amino acid residue (TLR2 Asp-730) in Region II also resulted in decreased activity in agreement with our model, providing new insights into the structure-function relationship of TLR2/1 TIR domains.

Citing Articles

Structural basis for TIR domain-mediated innate immune signaling by Toll-like receptor adaptors TRIF and TRAM.

Manik M, Pan M, Xiao L, Gu W, Kim H, Pospich S Proc Natl Acad Sci U S A. 2025; 122(2):e2418988122.

PMID: 39786929 PMC: 11745336. DOI: 10.1073/pnas.2418988122.


Porphyromonas gingivalis induction of TLR2 association with Vinculin enables PI3K activation and immune evasion.

Pandi K, Angabo S, Gnanasekaran J, Makkawi H, Eli-Berchoer L, Glaser F PLoS Pathog. 2023; 19(4):e1011284.

PMID: 37023213 PMC: 10112799. DOI: 10.1371/journal.ppat.1011284.


Structural and Functional Characterization of Rv0792c from Mycobacterium tuberculosis: Identifying Small Molecule Inhibitor against HutC Protein.

Chauhan N, Anand A, Sharma A, Dhiman K, Gosain T, Singh P Microbiol Spectr. 2022; 11(1):e0197322.

PMID: 36507689 PMC: 9927256. DOI: 10.1128/spectrum.01973-22.


Platelets, Bacterial Adhesins and the Pneumococcus.

Jahn K, Kohler T, Swiatek L, Wiebe S, Hammerschmidt S Cells. 2022; 11(7).

PMID: 35406684 PMC: 8997422. DOI: 10.3390/cells11071121.


Modulation of Toll-like receptor 1 intracellular domain structure and activity by Zn ions.

Lushpa V, Goncharuk M, Lin C, Zalevsky A, Talyzina I, Luginina A Commun Biol. 2021; 4(1):1003.

PMID: 34429510 PMC: 8385042. DOI: 10.1038/s42003-021-02532-0.


References
1.
Brown V, Brown R, Ozinsky A, Hesselberth J, Fields S . Binding specificity of Toll-like receptor cytoplasmic domains. Eur J Immunol. 2006; 36(3):742-53. PMC: 2762736. DOI: 10.1002/eji.200535158. View

2.
Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley J . Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature. 2000; 408(6808):111-5. DOI: 10.1038/35040600. View

3.
Hajjar A, OMahony D, Ozinsky A, Underhill D, Aderem A, Klebanoff S . Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol. 2000; 166(1):15-9. DOI: 10.4049/jimmunol.166.1.15. View

4.
David L, Luo R, Gilson M . Ligand-receptor docking with the Mining Minima optimizer. J Comput Aided Mol Des. 2001; 15(2):157-71. DOI: 10.1023/a:1008128723048. View

5.
Carl V, Brown-Steinke K, Nicklin M, Smith Jr M . Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages. J Biol Chem. 2002; 277(20):17448-56. DOI: 10.1074/jbc.M111847200. View